Literature DB >> 14971888

Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.

Karnail S Atwal1, Paulina Wang, W Lynn Rogers, Paul Sleph, Hossain Monshizadegan, Francis N Ferrara, Sarah Traeger, David W Green, Gary J Grover.   

Abstract

In this paper we show that 4-aryl-CH2-imidazole-substituted benzopyran compounds with 3S,4R-stereochemistry are cardioprotective by inhibiting the F1F0 mitochondrial ATP hydrolase. Compounds (e.g., 13) with 3R,4S-stereochemistry act as mitochondrial KATP openers. This resulted from an inversion of stereochemistry for the F1F0 mitochondrial ATP hydrolase vs mitochondrial KATP. Structure-activity relationships for the inhibition of mitochondrial ATP hydrolase are also delineated. It is not clear how 13 (3R,4S) can selectively inhibit the hydrolytic activity of the F1F0 mitochondrial enzyme without interfering with the synthase activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971888     DOI: 10.1021/jm030291x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

Review 1.  Nitrite as a mediator of ischemic preconditioning and cytoprotection.

Authors:  Daniel Murillo; Christelle Kamga; Li Mo; Sruti Shiva
Journal:  Nitric Oxide       Date:  2011-01-26       Impact factor: 4.427

Review 2.  ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas.

Authors:  Sangjin Hong; Peter L Pedersen
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

Review 3.  Regulation of mitochondrial ATP synthase in cardiac pathophysiology.

Authors:  Qinqiang Long; Kevin Yang; Qinglin Yang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

4.  A Modified System for the Synthesis of Enantioenriched N-Arylamines through Copper-Catalyzed Hydroamination.

Authors:  Saki Ichikawa; Shaolin Zhu; Stephen L Buchwald
Journal:  Angew Chem Int Ed Engl       Date:  2018-06-12       Impact factor: 15.336

Review 5.  Natural products and other inhibitors of F1FO ATP synthase.

Authors:  Bhargav A Patel; Terin L D'Amico; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2020-09-03       Impact factor: 6.514

6.  Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols.

Authors:  Jonathan R Gledhill; Martin G Montgomery; Andrew G W Leslie; John E Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-13       Impact factor: 11.205

7.  Directed evolution of aminoglycoside phosphotransferase (3') type IIIa variants that inactivate amikacin but impose significant fitness costs.

Authors:  Joseph R Kramer; Ichiro Matsumura
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

8.  Selective removal of deletion-bearing mitochondrial DNA in heteroplasmic Drosophila.

Authors:  Nikolay P Kandul; Ting Zhang; Bruce A Hay; Ming Guo
Journal:  Nat Commun       Date:  2016-11-14       Impact factor: 14.919

9.  Emerging Potential of Immediate Early Response Gene X-1 in Cardiovascular and Metabolic Diseases.

Authors:  Mohd Shahid; Erin L Hermes; David Chandra; Mohammad Tauseef; M Rizwan Siddiqui; M Hafeez Faridi; Mei X Wu
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

10.  The compound BTB06584 is an IF1 -dependent selective inhibitor of the mitochondrial F1 Fo-ATPase.

Authors:  Fabrice Ivanes; Danilo Faccenda; Jemma Gatliff; Ahmed A Ahmed; Stefania Cocco; Carol Ho Ka Cheng; Emma Allan; Claire Russell; Michael R Duchen; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.